News

Although the FDA approval of lenacapavir as a twice-yearly form of preexposure prophylaxis (PrEP) is “momentous,” cost and access curb excitement, according to Jeremiah Johnson, executive director of ...
WHO endorses biannual injectable Lenacapavir for HIV prevention. This long-acting PrEP offers hope for high-risk groups and ...
PEPFAR was launched in 2003 to stop the spread of HIV in Africa. Now, although some funding remains for the program, many of ...
Thousands of adults age 50-plus are diagnosed with HIV every year, but an expanding menu of medications can help prevent ...
THE PHILIPPINE National AIDS Council (PNAC) and AIDS Healthcare Foundation (AHF) Philippines on Thursday said the procurement of the vaccine lenacapavir is underway following the rapid spike of human ...
TANZANIA is among countries expected to benefit from the upcoming rollout of injectable lenacapavir for HIV prevention, following a landmark recommendation by the World Health Organization (WHO).
New WHO guidelines endorse long-acting injectable lenacapavir for HIV prevention, Medicines Patent Pool expands licence for ...
The World Health Organisation (WHO) has raised concern over the stagnation of global HIV prevention efforts, announcing ...
The global recommendation – issued Monday at the International AIDS Conference in Kigali, Rwanda – comes about a month after ...
Kenya is set to roll out the long-acting injectable HIV Pre-Exposure prophylaxis (PrEP) Lenacapavir by January 2026 following ...
Lenacapavir received approval from the U.S. Food and Drug Administration (FDA) in June 2025 and has subsequently been endorsed in the updated World Health Organisation (WHO) guidelines on long-acting ...
Your premium access has ended, but the best of Nation.Africa is still within reach. Renew now to unlock exclusive stories and ...